FTC Theories Of Harm After Anesthesia Co. Ruling

M
Mintz

Contributor

Mintz is a general practice, full-service Am Law 100 law firm with more than 600 attorneys. We are headquartered in Boston and have additional US offices in Los Angeles, Miami, New York City, San Diego, San Francisco, and Washington, DC, as well as an office in Toronto, Canada.
They also highlighted the broader implications for private equity transactions in health care under the new FTC merger guidelines.
United States Texas Antitrust/Competition Law
To print this article, all you need is to be registered or login on Mondaq.com.

Antitrust Co-chairs Bruce Sokler and Joe Miller, along with Associate Payton Thornton co-authored an article in Law360 discussing key takeaways from a Texas judge's decision to dismiss a private equity firm from the Federal Trade Commission's lawsuits against the firm and US Anesthesia Partners Inc. They also highlighted the broader implications for private equity transactions in health care under the new FTC merger guidelines.

The authors wrote, "Dismissal of the private equity sponsor from the suit is not fatal to the underlying theme of the FTC's case, which will proceed against the anesthesia group defendant and could potentially advance the antitrust agencies' ability to unwind transactions that cumulatively increase a firm's power in a given market."

SOURCE

Law360

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

Mondaq uses cookies on this website. By using our website you agree to our use of cookies as set out in our Privacy Policy.

Learn More